MannKind (MNKD) Stock Continues to Gain Following Friday's Rally

NEW YORK (TheStreet) -- Shares of MannKind (MNKD) are gaining, up 5.01% to $4.19 in mid-morning trading Monday, continuing its rally from the prior session on Friday.

Analysts at Jefferies issued a note Friday morning saying they see "good interest" for use of MannKind's Afrezza drug.

Afrezza, the company's signature drug, is an inhalable product to treat diabetes.

The firm reiterated its "buy" rating with a price target of $9 following its recent Afrezza survey.

Jefferies surveyed 56 endocrinologists and primary care physicians about their expected use of Afrezza for diabetes.

The firm said in a note, In screening physicians, we found that 35% did not know about Afrezza. Those that did, however, expected to use Afrezza more frequently than we had expected, especially among type 1 diabetics.

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. The company is based in Valencia, Calif.

MNKD ChartMNKD data by YCharts

If you liked this article you might like

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Pharma Bro Martin Shkreli Awaits Jury Decision in Fraud Case

Mannkind in Free Fall After Changes to Insulin Product, Sales Force

Mannkind in Free Fall After Changes to Insulin Product, Sales Force